|
WO2021074157A1
|
|
Treatment of cancer with ilt-2 inhibitors
|
|
WO2020216697A1
|
|
Cd73 blocking antibodies
|
|
WO2020152081A1
|
|
Treatment of t cell lymphoma
|
|
WO2020136145A2
|
|
Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies
|
|
WO2020035345A1
|
|
Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
|
|
AU2019289646A1
|
|
Compositions and methods for treating cancer
|
|
WO2019206974A1
|
|
Methods for treating cancer by targeting nidogen-1
|
|
CN112004828A
|
|
Treatment of head and neck cancer
|
|
AU2018371114A1
|
|
Multispecific antigen binding proteins
|
|
CA3075371A1
|
|
Potentiating the effect of atp release
|
|
WO2019092148A1
|
|
Antibodies with functionalized glutamine residues
|
|
AU2018346447A1
|
|
Restoration of T cell activity via the CD39/CD73 axis
|
|
KR20200026253A
|
|
SIGLEC-9 neutralizing antibody
|
|
AU2018298673A1
|
|
Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
|
|
WO2018167267A1
|
|
Compositions and methods for treating cancer
|
|
WO2018141959A1
|
|
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
|
US2019367609A1
|
|
NKp46 BINDING AGENTS
|
|
WO2018115262A1
|
|
Heterodimeric antigen binding proteins
|
|
WO2018083080A2
|
|
Nkp46 ligand
|
|
AU2017345203A1
|
|
Treatment with anti-KIR3DL2 agents
|
